Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Mar 2;6(1):105.
doi: 10.1038/s41392-021-00518-2.

'nAb' the self-reactive activity in the COVID-19 combat

Madhusudhanan Narasimhan #  1 , Lenin Mahimainathan #  1 , Alagarraju Muthukumar  2
Affiliations
Comment

'nAb' the self-reactive activity in the COVID-19 combat

Madhusudhanan Narasimhan et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Non-self-reacting antibodies and SARS-CoV-2 infection. Do the passive antibody supply strategy-based CPT require exclusion of autoreactive and non-nAbs, and retention of Abs with non-self-reactive-neutralizing activity to improve efficacy? (left). Non-self-reactive-neutralizing antibody proposed to be a potent therapy for inhibiting the SARS-CoV-2 activity (right). CPT convalescent plasma therapy, nAb neutralizing antibody, s-nAb self-reactive-neutralizing antibody, ns-nAb non-self-reactive-neutralizing antibody, T-ns-nAb therapeutic non-self-reactive antibody
See this image and copyright information in PMC

Comment on

  • A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model.
    Kreye J, Reincke SM, Kornau HC, Sánchez-Sendin E, Corman VM, Liu H, Yuan M, Wu NC, Zhu X, Lee CD, Trimpert J, Höltje M, Dietert K, Stöffler L, von Wardenburg N, van Hoof S, Homeyer MA, Hoffmann J, Abdelgawad A, Gruber AD, Bertzbach LD, Vladimirova D, Li LY, Barthel PC, Skriner K, Hocke AC, Hippenstiel S, Witzenrath M, Suttorp N, Kurth F, Franke C, Endres M, Schmitz D, Jeworowski LM, Richter A, Schmidt ML, Schwarz T, Müller MA, Drosten C, Wendisch D, Sander LE, Osterrieder N, Wilson IA, Prüss H. Kreye J, et al. Cell. 2020 Nov 12;183(4):1058-1069.e19. doi: 10.1016/j.cell.2020.09.049. Epub 2020 Sep 23. Cell. 2020. PMID: 33058755 Free PMC article.

References

    1. Kreye J, et al. A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model. Cell. 2020;183:1058–1069. doi: 10.1016/j.cell.2020.09.049. - DOI - PMC - PubMed
    1. Kreye J, et al. Do cross-reactive antibodies cause neuropathology in COVID-19? Nat. Rev. Immunol. 2020;20:645–646. doi: 10.1038/s41577-020-00458-y. - DOI - PMC - PubMed
    1. Franke C, et al. High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Brain Behav. Immun. 2020;1591:32465-X. - PMC - PubMed
    1. Mulder, J. et al. Autoimmune encephalitis presenting with malignant catatonia in a 40-year-old male patient with Covid-19. Preprint at 10.1101/2020.07.23.20160770v1 (2020). - PubMed
    1. Sheahan TP, Frieman MB. The continued epidemic threat of SARS-CoV-2 and implications for the future of global public health. Curr. Opin. Virol. 2020;40:37–40. doi: 10.1016/j.coviro.2020.05.010. - DOI - PMC - PubMed